Hepatitis C virus escape studies for human monoclonal antibody AR4A reveal isolate-specific resistance and a high barrier to resistance
The Journal of infectious diseases, 2018.
Global control of hepatitis C virus (HCV) depends on development of a prophylactic vaccine. We studied escape for cross-genotype-reactive neutralizing antibody AR4A, providing valuable information for HCV vaccine design. We cultured HCV Core-NS2 recombinants H77(genotype 1a)/JFH1 or the highly-antibody-sensitive hypervariable region 1 (HV...More
Full Text (Upload PDF)